tiprankstipranks
Advertisement
Advertisement

CTSO Stock Latest News

CytoSorbents Shareholders Approve Governance Measures and Reverse Split
Company AnnouncementsCytoSorbents Shareholders Approve Governance Measures and Reverse Split
17h ago
8K
CTSO
Cytosorbents Advances Toward Operating Cash Flow Breakeven
PremiumCompany Announcements
Cytosorbents Advances Toward Operating Cash Flow Breakeven
8d ago
8K
CTSO
CytoSorbents: Neutral Rating Reiterated as Operational Progress Offsets Market and Regulatory Risks; $0.75 Price Target Maintained
PremiumRatings
CytoSorbents: Neutral Rating Reiterated as Operational Progress Offsets Market and Regulatory Risks; $0.75 Price Target Maintained
8d ago
CTSO
Is CTSO a Buy, Before Earnings?
PremiumPre-Earnings
Is CTSO a Buy, Before Earnings?
11d ago
CTSO
Cytosorbents Faces Nasdaq Compliance and Delisting Risk
PremiumCompany Announcements
Cytosorbents Faces Nasdaq Compliance and Delisting Risk
1M ago
8K
CTSO
CytoSorbents Advances FDA Pathway for DrugSorb Programs
PremiumCompany AnnouncementsCytoSorbents Advances FDA Pathway for DrugSorb Programs
2M ago
8K
CTSO
Cytosorbents Earnings Call Balances Progress and Pressure
Premium
Company Announcements
Cytosorbents Earnings Call Balances Progress and Pressure
3M ago
CTSO
Cytosorbents Earnings Call Balances Progress And Pressure
Premium
Company Announcements
Cytosorbents Earnings Call Balances Progress And Pressure
3M ago
CTSO
CytoSorbents reports Q1 adjusted EPS (5c) vs. (6c) last year
PremiumThe Fly
CytoSorbents reports Q1 adjusted EPS (5c) vs. (6c) last year
3M ago
CTSO
CTSO Earnings this Week: How Will it Perform?
PremiumPre-Earnings
CTSO Earnings this Week: How Will it Perform?
3M ago
CTSO
CytoSorbents Receives Nasdaq Extension to Regain Compliance
PremiumCompany Announcements
CytoSorbents Receives Nasdaq Extension to Regain Compliance
5M ago
8K
CTSO
Cytosorbents’ Earnings Call Balances Progress and Risk
PremiumCompany Announcements
Cytosorbents’ Earnings Call Balances Progress and Risk
5M ago
CTSO
CytoSorbents: Neutral Stance as U.S. DrugSorb-ATR Opportunity Offsets Near-Term Execution and Regulatory Risks
PremiumRatingsCytoSorbents: Neutral Stance as U.S. DrugSorb-ATR Opportunity Offsets Near-Term Execution and Regulatory Risks
5M ago
CTSO
CytoSorbents Narrows Losses Amid Strategic Shift and Growth
Premium
Company Announcements
CytoSorbents Narrows Losses Amid Strategic Shift and Growth
5M ago
8K
CTSO
CytoSorbents reports Q4 adjusted EPS (7c) vs. (3c) last year
Premium
The Fly
CytoSorbents reports Q4 adjusted EPS (7c) vs. (3c) last year
5M ago
CTSO
CTSO Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
CTSO Upcoming Earnings Report: What to Expect?
5M ago
CTSO
CytoSorbents sees Q4 revenue $9.2M, consensus $9.85M
PremiumThe Fly
CytoSorbents sees Q4 revenue $9.2M, consensus $9.85M
7M ago
CTSO
CytoSorbents sees FY25 revenue $37M, consensus $37.67M
PremiumThe Fly
CytoSorbents sees FY25 revenue $37M, consensus $37.67M
7M ago
CTSO
Cytosorbents Corp’s Earnings Call: Growth Amid Challenges
PremiumCompany Announcements
Cytosorbents Corp’s Earnings Call: Growth Amid Challenges
9M ago
CTSO
CytoSorbents price target lowered to 75c from $1 at H.C. Wainwright
PremiumThe FlyCytoSorbents price target lowered to 75c from $1 at H.C. Wainwright
9M ago
CTSO
CytoSorbents Reports Strong Q3 2025 Growth and Strategic Advances
Premium
Company Announcements
CytoSorbents Reports Strong Q3 2025 Growth and Strategic Advances
9M ago
CTSO
CytoSorbents reports Q3 adjusted EPS (4c), consensus (5c)
Premium
The Fly
CytoSorbents reports Q3 adjusted EPS (4c), consensus (5c)
9M ago
CTSO

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >